Eli Lilly & Co. vs. Oric Pharmaceuticals, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| LLY | ORIC | |
|---|---|---|
| Market Cap | $1.04 trillion | $1.34 billion |
| Revenue (TTM) | $65.18 billion | — |
| Net Income (TTM) | $20.64 billion | $-140,351,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | ORIC | |
|---|---|---|
| P/E Ratio | 50.97 | — |
| Price / Book | 39.31 | 3.52 |
| Price / Sales | 16.01 | — |
ORIC leads on 1 of 1 valuation factors.
Profitability
| LLY | ORIC | |
|---|---|---|
| Net Margin | 31.67% | — |
| Return on Equity | 77.78% | -36.81% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | ORIC | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 30.15 | — |
LLY and ORIC split the dividend factors evenly.
Risk & Sentiment
| LLY | ORIC | |
|---|---|---|
| Short Interest | 1.29% | 0.65% |
ORIC leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, ORIC overview, ORIC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.